The Texas A&M University system has announced a partnership with pharmaceutical giant GlaxoSmithKline to establish a $91 million influenza vaccine-manufacturing facility in Bryan-College Station. Gov. Rick Perry said the company will generate billions of dollars worth of expenditures per year and will create close to 7,000 jobs.

The TAMUS influenza vaccine-manufacturing center will facilitate a rapid national vaccine response in the event of a pandemic.

The announcement was made at a press conference in Austin Tuesday morning, more than a hundred miles away from the the Center of Innovation in Advanced Development and Manufacturing in the Bryan-College Station biocorridor.

The 196-acre corridor is along the shared border near Easterwood Airport. City officials worked alongside Texas A&M for years to develop the area in hopes of luring biotechnology companies and startups to Bryan-College Station.

Those efforts were, in part, realized on Tuesday.

“We are honored to welcome GSK to Texas A&M as a key partner in the Center for Innovation,” said system Chancellor John Sharp in a press release. “GSK’s dedication to public service is well-aligned with the Texas A&M tradition of serving the nation and defining its future through research and scholarship. Equally important is the cultural and philosophical match between GSK and the A&M System, as reflected by GSK’s desire to collaborate with academia and the U.S. government, and their ongoing commitment to helping address global health scourges such as pandemic influenza and malaria.”

Antoon Loomans, Senior Vice President, GSK Vaccines, represented GSK at the event.

“GSK is privileged to deepen our commitment to U.S. public health, as part of this unprecedented public-private collaboration to protect against pandemics and bio-threats,” said Loomans in the release. “In Texas A&M we have found a partner with a rich tradition of service, and with pioneering technologies that will benefit the entire pharmaceutical industry in making vaccines available and accessible to all in need.”

The center’s influenza manufacturing facility will be able to supply 50 million doses of pandemic influenza vaccine within four months of an outbreak, according to the release. The federal government’s Biomedical Advanced Research and Development Authority conceived the public-private formula to assure a strong biosecurity product development and manufacturing base on U.S. soil, ensuring that the nation would have rapid access to vaccines and therapeutics in the advent of influenza pandemics, or chemical, biological, radiological, and nuclear attacks.

“Today’s announcement is a huge win for Texas and for the nation,” Perry said. “The Texas A&M Center, anchored by this facility, is expected to bring more than $41 billion in expenditures within the state of Texas over the next 25 years, and will add more than 6,800 direct and related jobs to Texas.”

Get daily news, sports, opinions, entertainment and more, delivered every morning.

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Recommended for you

(4) comments


Of all the companies with whom A&M could have partnered, GlaxoSmithKline is the worst choice.

Type "GlaxoSmithKline, scandals" into Google and read until you agree.

This is quality of decision has become typical with Mr. Sharp.


i'm against mr sharp and everything he stands for because he does'nt care about a&m employees period..

Nunya Bidness

Ooohhh how witty you are slowpoke. Do you not want these new employees to come from out of state, or are you just against economic growth in B/CS?


i wonder if sharp is going to outsource those jobs to people in other states.

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.